Lakefront Biotherapeutics NV (LKFT) shareholders
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. Joint filing with Gilead Therapeutics A1 Unlimited Company (29.90%) | 20,981,010 | 29.90% | 13D (active) amendment | Jan 7, 2025 |
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (13.22%), EcoR1 Capital Fund Qualified, L.P. (12.43%) | 8,714,522 | 13.22% | 13D (active) amendment | Jul 24, 2025 |
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (11.84%), EcoR1 Capital Fund Qualified, L.P. (11.14%) | 7,803,202 | 11.84% | 13D (active) amendment | May 15, 2025 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (8.40%), Tang Capital Partners, LP (5.00%) | 5,559,674 | 8.40% | 13G (passive) | Oct 27, 2025 |
| Eli Samaha Joint filing with Madison Avenue International LP (5.50%), Madison Avenue Partners, LP (5.50%) and 3 more | 3,606,203 | 5.50% | 13G (passive) | Jun 15, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LKFT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 16,707,477 | – | $500.16M | – | 30.34% |
| Tang Capital Management LLC | 3,785,991 | – | $113.50M | – | 5.16% |
| Madison Avenue Partners, LP | 3,447,807 | – | $103.37M | +982,628 | 4.45% |
| Prosight Management, LP | 2,043,344 | – | $61.26M | +493,344 | 10.56% |
| EcoR1 Capital, LLC | 1,667,119 | – | $49.98M | – | 2.43% |
| Ameriprise Financial Inc | 1,272,249 | – | $38.14M | −152,425 | 0.01% |
| DME Capital Management, LP | 482,746 | – | $14.47M | – | 0.37% |
| Renaissance Technologies LLC | 407,800 | – | $12.23M | +92,400 | 0.02% |
| BlackRock, Inc. | 338,152 | – | $10.14M | +26,046 | 0.00% |
| Point72 Asset Management, L.P. | 269,814 | – | $8.09M | −62,311 | 0.01% |
| D. E. Shaw & Co., Inc. | 197,844 | – | $5.93M | −17,874 | 0.00% |
| Millennium Management LLC | 181,090 | – | $5.43M | +73,178 | 0.00% |
| UBS Group AG | 168,148 | – | $5.04M | −7,141 | 0.00% |
| Susquehanna International Group, Llp | 151,886 | – | $4.55M | +138,499 | 0.00% |
| DAFNA Capital Management LLC | 130,175 | – | $3.90M | – | 0.74% |
| Citadel Advisors LLC | 88,343 | – | $2.65M | −36,085 | 0.00% |
| Two Sigma Investments, LP | 81,749 | – | $2.45M | +55,889 | 0.00% |
| Norges Bank | 76,879 | – | $2.30M | New | 0.00% |
| Alps Advisors Inc | 65,523 | – | $1.96M | +11,862 | 0.01% |
| Goldman Sachs Group Inc | 56,581 | – | $1.70M | +11,210 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | 32M | 9 / 26 | 28 / 21 | 2M | 1M |
| Q1 2026 | 90 | 31M | 16 / 33 | 28 / 15 | 1M | 1M |
| Q4 2025 | 91 | 31M | 16 / 28 | 33 / 16 | 1M | 1M |
| Q3 2025 | 92 | 31M | 18 / 31 | 29 / 11 | 3M | 3M |
| Q2 2025 | 85 | 32M | 21 / 25 | 24 / 18 | 5M | 4M |
| Q1 2025 | 83 | 31M | 17 / 22 | 30 / 15 | 3M | 3M |
| Q4 2024 | 81 | 31M | 12 / 24 | 24 / 10 | 19M | 2M |
| Q3 2024 | 79 | 14M | 11 / 25 | 24 / 16 | 2M | 8M |
| Q2 2024 | 85 | 20M | 12 / 38 | 18 / 9 | 1M | 2M |
| Q1 2024 | 82 | 21M | 9 / 27 | 28 / 14 | 2M | 1M |
| Q4 2023 | 88 | 20M | 20 / 36 | 17 / 5 | 2M | 1M |
| Q3 2023 | 73 | 20M | 6 / 32 | 20 / 8 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
17 funds held LKFT in Q2 2026, 22% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LKFT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Columbia Overseas Value Fund | 746,801 | – | $21.17M | 0.31% | May 31, 2026 |
| iShares Biotechnology ETF | 292,580 | – | $8.77M | 0.10% | Jun 30, 2026 |
| Columbia Variable Portfolio - Overseas Core Fund | 280,317 | – | $8.40M | 0.22% | Jun 30, 2026 |
| Columbia Overseas Core Fund | 90,697 | – | $2.57M | 0.26% | May 31, 2026 |
| ALPS Medical Breakthroughs ETF | 67,945 | – | $1.93M | 1.19% | May 31, 2026 |
| Avantis International Equity ETF | 30,449 | – | $863.23K | 0.01% | May 31, 2026 |
| International Value Fund | 28,283 | – | $801.82K | 0.16% | May 31, 2026 |
| ActivePassive International Equity ETF | 18,273 | – | $518.04K | 0.05% | May 31, 2026 |
| Steward Values Enhanced International Fund | 16,569 | – | $450.84K | 0.13% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 10,150 | – | $287.75K | 0.00% | May 31, 2026 |
| Avantis International Small Cap Equity ETF | 6,762 | – | $191.70K | 0.06% | May 31, 2026 |
| Avantis International Equity Fund | 2,478 | – | $70.25K | 0.01% | May 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 794 | – | $22.51K | 0.03% | May 31, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 548 | – | $15.54K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 100 | – | $3.00K | 0.00% | Jun 30, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 6 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lakefront Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,727 shares on Oct 9, 2026 over the last 90 days.
See a number that looks wrong?